Skip to main content
Download PDF

Correction: Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy

Alzheimer's Research & Therapy volume 15, Article number: 18 (2023) Cite this article

The Original Article was published on 30 November 2020

Correction: Alz Res Ther 12, 159 (2020)

https://doi.org/10.1186/s13195-020-00727-x

Following publication of the original article [1], the authors reported a mistake in Fig. 4. Graph C must have been inadvertently copied into the place for graph A when making the figure. The corrected graph similarly did not show any significant relationships and does not change the interpretation of the results. The figure legend and description of the figure in the text remain correct.

Fig. 4
figure 1

Quantification of Lewy bodies and Lewy neurites in PD and DLB. IGG-1, I GG-2, IGG-3. No difference in % area LBs in the temporal cortex and SN of PD cases was observed between each of the antibodies and NOV (a, c). b However, significantly more LNs were detected with IGG-2 and IGG-1 antibodies compared to IGG-3 and NOV (P < 0.0001); in the TC, there was no difference between IGG-3 and NOV. In addition, IGG-2 stained more LNs than IGG-1 in the temporal cortex of PD cases (P < 0.0001). d In the SN of PD cases, the % area LNs was greater for IGG-1 (P = 0.002), IGG-2 (P < 0.0001) and IGG-3 (P < 0.0001) compared to NOV. in addition IGG-3 was significantly greater than IGG-1 (P = 0.028) (d). e % area LBs detected by IGG-3 (P = 0.006) and IGG-2 (P = 0.001) was significantly greater than NOV. In addition, IGG-2 stained more LBs than IGG-1 in TC of DLB cases (P = 0.014). f Significantly more LNs were detected with IGG-2 compared to IGG-1, IGG-3 and NOV (P < 0.0001). In addition, IGG-1 stained more LNs than NOV in TC of DLB cases (P < 0.0001), but there was no difference between IGG-3 and NOV. g IGG-2 (P = 0.001) and IGG-3 (P < 0.0001) showed greater % area LBs in SN of DLB cases compared to NOV. IGG-3 also detected a higher level of LBs compared to IGG-1 (P = 0.002). h All antibodies showed significantly higher detection of LNs in SN compared to NOV in which the greatest difference occurred with IGG-3 (P < 0.0001) and the smallest with IGG-1 (P = 0.017). % area LNs with IGG-3 was also significantly higher than both IGG-1 (P < 0.0001) and IGG-2 (P = 0.001). In addition, IGG-2 was greater than IGG-1 (P = 0.013). Error bars show mean ± 95% CI

Full size image

The original article [1] has been updated.

Below is the corrected Fig. 4.

Reference

  1. Nimmo JT, Verma A, Dodart JC, et al. Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy. Alz Res Ther. 2020;12:159. https://doi.org/10.1186/s13195-020-00727-x.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Neurosciences. Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK

    Jacqui T. Nimmo, Roxana O. Carare & James A. R. Nicoll

  2. United Neuroscience, Dublin, Republic of Ireland

    Ajay Verma, Jean-Cosme Dodart & Chang Yi Wang

  3. Institute Francois Jacob (MIRCen), CEA and Laboratory of Neurodegenerative Diseases, CNRS, Paris, France

    Jimmy Savistchenko & Ronald Melki

Authors
  1. Jacqui T. Nimmo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ajay Verma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jean-Cosme Dodart
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chang Yi Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jimmy Savistchenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ronald Melki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Roxana O. Carare
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. James A. R. Nicoll
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James A. R. Nicoll.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nimmo, J.T., Verma, A., Dodart, JC. et al. Correction: Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy. Alz Res Therapy 15, 18 (2023). https://doi.org/10.1186/s13195-022-01156-8

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s13195-022-01156-8

Alzheimer's Research & Therapy

ISSN: 1758-9193